HKMPF - Week In Review: Suzhou Abogen Raises $700 Million For mRNA COVID Vaccine
- Suzhou Abogen Biosciences raised over $700 million in a record-breaking Series C round to support a Phase III trial of its mRNA COVID-19 vaccine. The company has completed a Phase II trial of the vaccine but hasn't released any data from the trial.
- BeyondSpring, a New York City-China company, signed a $200 million agreement with Jiangsu Hengrui Pharma to partner China commercialization of its lead oncology drug.
- Beijing Kangle Weishi Biotech completed a $157 million pre-IPO financing round to develop recombinant vaccines that are based on its virus-like particle (VLP) platform.
- SuzhouAlphamab Oncology out-licensed China rights for its anti-HER2 bispecificantibody to CSPC Pharma in a deal worth up to $150 million, plus royalties.
For further details see:
Week In Review: Suzhou Abogen Raises $700 Million For mRNA COVID Vaccine